To cite this paper use one of the standards below:
In our laboratory, we developed the first bioprinter using recyclable material, through which we began the construction of 3D models with an alginate and gelatin matrix for experiments focused on glioblastoma (GL261) and hepatocellular carcinoma (HepG2), given their significant medical relevance. Glioblastoma is notorious for its low life expectancy after diagnosis, while hepatocellular carcinoma is one of the main metastatic sites. Our confocal microscopy analyzes revealed that models with GL261 showed a significant reduction in cell viability seven days after printing, while models with HepG2 maintained good viability after 15 days. The alginate matrix may require other components to support the viability of GL261. Both models showed low cell density in histological sections, which can be improved by increasing the culture time. In collaboration with PUC-RIO, we synthesized nanoparticles based on rare earth elements that exhibit fluorescence under X-ray radiation. The europium-doped gadolinium nanoparticle showed light emission when irradiated, suggesting that these nanoparticles can activate photosensitizers in deep-seated tumors. Our experiments demonstrated that these nanoparticles are capable of activating photosensitizers in the red range under low-intensity X-rays. 3D bioprinting allows the creation of complex tumor structures that replicate the in vivo microenvironment, providing a more realistic model for therapeutic evaluation. The synthesis of fluorescent nanoparticles opens new avenues for the development of more efficient and precise PDT systems. Our results indicate that the combination of low-energy X-rays and nanoparticles may be promising. However, it is necessary to further our studies to ensure reproducible results and, eventually, bring this therapy into clinical practice. We have a partnership that allows the evaluation of patients' primary tumor cells; however, due to the low frequency of surgeries, we have not yet carried out trials with these samples.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper